In this study, we report a plasma proteomic analysis of a mouse MCF7 xenograft, using a novel platform named M-LAC (multilectin affinity chromatography), in an attempt to identify putative serum biomarkers of tumor presence and response to therapy. The use of the M-LAC platform enabled us to focus on secreted proteins as well as remove interference from serum albumin and other nonglycosylated proteins. The study focused on the MCF7 human xenograft tumor model which enabled us to distinguish tumor proteins (human peptide sequences) from host-derived murine proteins, potentially discriminating tumor- versus supporting tissue-derived markers. A large set of murine proteins was identified in this study, including several signaling molecules suc...
The discovery of biomarkers that are readily accessible through the circulating blood and are select...
cancer and are important in serum studies, for which glycosylation is a common posttranslational mod...
We have applied a serologic proteomic workflow involving three complementary MS approaches to a tiss...
<div><p>The most cancer-specific biomarkers in blood are likely to be proteins shed directly by the ...
The complexity of the human plasma proteome represents a substantial challenge for biomarker discove...
Abstract Early detection of cancer is vital for the best chance of successful treatment, but half of...
The complexity and heterogeneity of the human plasma proteome have presented significant challenges ...
Tumor-derived, circulating proteins are potentially useful as biomarkers for detection of cancer, fo...
A proof-of-concept demonstration of the use of label-free quantitative glycoproteomics for biomarker...
With advancements in the analytical technologies and methodologies in proteomics, there is great int...
To survive and metastasize, tumors interact with surrounding tissues by secreting growth factors and...
This study describes a novel xenograft-based biomarker discovery platform and proves its usefulness ...
With advancements in the analytical technologies and methodologies in proteomics, there is great int...
BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains...
The most widely used cancer animal model is the human-murine tumor xenograft. Unbiased molecular dis...
The discovery of biomarkers that are readily accessible through the circulating blood and are select...
cancer and are important in serum studies, for which glycosylation is a common posttranslational mod...
We have applied a serologic proteomic workflow involving three complementary MS approaches to a tiss...
<div><p>The most cancer-specific biomarkers in blood are likely to be proteins shed directly by the ...
The complexity of the human plasma proteome represents a substantial challenge for biomarker discove...
Abstract Early detection of cancer is vital for the best chance of successful treatment, but half of...
The complexity and heterogeneity of the human plasma proteome have presented significant challenges ...
Tumor-derived, circulating proteins are potentially useful as biomarkers for detection of cancer, fo...
A proof-of-concept demonstration of the use of label-free quantitative glycoproteomics for biomarker...
With advancements in the analytical technologies and methodologies in proteomics, there is great int...
To survive and metastasize, tumors interact with surrounding tissues by secreting growth factors and...
This study describes a novel xenograft-based biomarker discovery platform and proves its usefulness ...
With advancements in the analytical technologies and methodologies in proteomics, there is great int...
BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains...
The most widely used cancer animal model is the human-murine tumor xenograft. Unbiased molecular dis...
The discovery of biomarkers that are readily accessible through the circulating blood and are select...
cancer and are important in serum studies, for which glycosylation is a common posttranslational mod...
We have applied a serologic proteomic workflow involving three complementary MS approaches to a tiss...